مانا بورس

#Dischloine raises rates In order to observe the provisions of Article 13 of the Information Disclosure Instructions, the sales rate of some of the company's products has increased to cover the costs of raw material prices and packaging items due to the future sales budget of the future, the impact of increased rates on sales is about 10 % (4 months of sales).

Pharmaceutical companies' sales rise in August Out of the total sales reports of 4 pharmaceutical companies in August, the following companies have shown the best sales growth compared to previous periods: #KBC #Dabur #Dadam #Medicine #Dalber #Valley #Dukimi #Dischool #Dallek #Caspian #Medication 📱 @fardaname

#Buy the lineup queue

#Shapxa in August 5567, July 5085 and June 5025 billion Rials were 8 months 34623 billion riyals, 50% longer than the same period. 6 months 23970 billion rials, 3 months 11767 billion rials

#Dabur also done well In the first 2 months, 4800 billion riyals and June 3,000 billion riyals were sold 3 months 7800 billion rials The bullet was also good and sold 3100 billion riyals and 3202 billion rials August 5 months reached 14819 billion rials. The same period last year was 9089 billion rials

#Mishangarne was sold in August 35402 and July 39255 billion rials and reached 154369 billion rials and the same period was 113567 billion rials.

#Sugar had a better summer The share of June was 2 billion riyals and July 2925 billion rials and 2401 billion rials in August and 5 months 11476 billion riyals and the same period was 10917 billion rials. The six months was 2 billion riyals.

#Ghazar sells interesting sales and sold 10423 billion Rials August 8046 and July 10423 A share that sold 3 months 10784 billion riyals 5 months sold 36131 billion riyals and the same period was 23180 billion rials

#Horizon made a special summer and recorded a billionaire August 147022 and July 132014 and reached 676365 billion.

18 fonts from #Dozravi Products increased rates The previous rate of 12,659 Rials New rate of 16,335 Rials Product / Service Specifications Product sales or service in the previous fiscal year 2,567,346 million Rials Product sales ratio or service to total corporate revenue in the previous fiscal year 24 % Respect for the provisions of Article 13 of the Executive Information Instructions provides the sales rate of 18 of its products to cover the costs of increased costs based on the Food and Drug Administration's license.